ProShare Advisors’s Castle Biosciences CSTL Stock Holding History

ProShare Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,478	Closed	-$252K	–	1910
2025 Q4	$252K	Buy	+6,478	New	+$209K	﹤0.01%	1562
2025 Q1	–	Sell	-8,613	Closed	-$230K	–	2133
2024 Q4	$230K	Buy	+8,613	New	+$262K	﹤0.01%	1818
2022 Q2	–	Sell	-6,625	Closed	-$298K	–	1861
2022 Q1	$298K	Sell	6,625 -1,593	-19%	-$65.8K	﹤0.01%	1635
2021 Q4	$352K	Buy	8,218 +111	+1%	+$5.8K	﹤0.01%	1690
2021 Q3	$539K	Sell	8,107 -1,924	-19%	-$135K	﹤0.01%	1164
2021 Q2	$736K	Buy	10,031 +2,758	+38%	+$182K	﹤0.01%	1241
2021 Q1	$498K	Buy	7,273 +1,573	+28%	+$118K	﹤0.01%	1441
2020 Q4	$383K	Buy	5,700 +1,091	+24%	+$59.1K	﹤0.01%	1429
2020 Q3	$237K	Buy	+4,609	New	+$205K	﹤0.01%	1326

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's CSTL Position: Q1 2026 in Review

ProShare Advisors sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 6,478 shares — an estimated $252K sold.

ProShare Advisors first reported a position in CSTL in Q3 2020 and held it in 9 quarters. The position peaked at $736K in Q2 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

ProShare Advisors reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 6,478 Castle Biosciences shares in Q1 2026, an estimated $252K.
ProShare Advisors first reported a position in Castle Biosciences in Q3 2020 and held it in 9 quarters.
ProShare Advisors's Castle Biosciences position peaked at $736K in Q2 2021.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.